InspireMD submits carotid stent for FDA premarket approval - MassDevice
InspireMD submits FDA premarket approval for CGuard Prime carotid stent system, based on C-GUARDIANS trial data showing 1.95% major adverse event rate at 12 months, aiming for U.S. approval for stroke prevention.
Reference News
InspireMD submits carotid stent for FDA premarket approval - MassDevice
InspireMD submits FDA premarket approval for CGuard Prime carotid stent system, based on C-GUARDIANS trial data showing 1.95% major adverse event rate at 12 months, aiming for U.S. approval for stroke prevention.